Walt Disney Co vs Cassava Sciences Inc — how do they compare? Walt Disney Co trades at $103.07 (market cap $178.76B), while Cassava Sciences Inc trades at $0.95 (market cap $47.75M). The key difference: Walt Disney Co is far larger — about 3743.7× Cassava Sciences Inc's market cap, and Walt Disney Co pays a 1.45% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| DIS | FLNA | |
|---|---|---|
Market Cap | $178.76B | $47.75M |
Volume | 7,546,013 | — |
Sector | Media | Health |
52-Week High | $118.86 | $4.64 |
52-Week Low | $92.40 | $0.87 |
Enterprise Value | $219.62B | -$34.93M |
Dividend Yield | 1.45% | — |
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $103.20, down 1.62% on the day, amid a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $2.06 exceeding estimates by $0.20. Revenue growth has been steady, reaching $94.43 billion in 2025, while net income surged to $12.40 billion. Analyst sentiment remains positive with a consensus price target of $126.00, representing a 22% upside. Recent news highlights advertising opportunities with major events like the Super Bowl and ongoing FCC regulatory challenges.
The outlook for Disney is favorable, driven by earnings momentum, strategic investments in parks and streaming, and a dominant position in entertainment. Key risks include regulatory disputes with the FCC, box office underperformance of recent films, and economic sensitivity. With a P/E of 21.35 and robust cash flow, the stock offers value for long-term investors despite near-term volatility.
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Trailing returns across standard periods
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →